The authors reported that their proteomics-guided analyses of 49 childhood ALL cell lines, generated a comprehensive resource of biomarkers and drug sensitivities as well as the identification of potential therapeutic vulnerability to target the MEF2D/HNRNPUL1 fusion protein in a high-risk subtype of the disease. This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.